CATX (Perspective Therapeutics) Accumulated Depreciation: $-8.47 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CATX Perspective Therapeutics Inc CATX
30 GF Score
Price $2.92
! 2 Warning Signs
View Full Analysis

What is Perspective Therapeutics Accumulated Depreciation?

Perspective Therapeutics CATX +3.91% 30 Accumulated Depreciation is $-8.47 Mil as of Jun. 2026. GuruFocus rates CATX with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Perspective Therapeutics's quarterly accumulated depreciation increased from Dec. 2025 ($-6.20 Mil) to Mar. 2026 ($-7.33 Mil) and increased from Mar. 2026 ($-7.33 Mil) to Jun. 2026 ($-8.47 Mil).

Perspective Therapeutics's annual accumulated depreciation increased from Dec. 2023 ($-0.67 Mil) to Dec. 2024 ($-2.96 Mil) and increased from Dec. 2024 ($-2.96 Mil) to Dec. 2025 ($-6.20 Mil).

Perspective Therapeutics Accumulated Depreciation Related Terms

Perspective Therapeutics Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Perspective Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perspective Therapeutics Accumulated Depreciation Chart

Perspective Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.25 -7.50 -0.67 -2.96 -6.20

Perspective Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.42 -5.20 -6.20 -7.33 -8.47
CATX
30GF Score
Perspective Therapeutics Inc CATX
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perspective Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $-8.47 Mil mean?
Perspective Therapeutics (CATX) has a Accumulated Depreciation of $-8.47 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Perspective Therapeutics and its competitors.
Is Perspective Therapeutics' Accumulated Depreciation too high?
Perspective Therapeutics' current Accumulated Depreciation is $-8.47 Mil. Overall, Perspective Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' Accumulated Depreciation compare to VMD and MOBI?
Perspective Therapeutics' Accumulated Depreciation of $-8.47 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Medical Devices & Instruments company?
A good Accumulated Depreciation depends on the Medical Devices & Instruments industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Perspective Therapeutics and its competitors. Perspective Therapeutics's current Accumulated Depreciation is $-8.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (CATX) has a current Accumulated Depreciation of $-8.47 Mil. The current Accumulated Depreciation is $-8.47 Mil. Perspective Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Perspective Therapeutics (CATX), the current Accumulated Depreciation is $-8.47 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Perspective Therapeutics Business Description

Other Exchanges AAJ0:Germany
Address 2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
30GF Score

Get the complete analysis for CATX

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.92
Price